Switching to sirolimus monotherapy for De Novo tumors after liver transplantation. A preliminary experience

Hepato-Gastroenterology

Volumn 58, Issue 105, 2011, Pages 115-121

  Jiménez Romero, Carlos ^a   Manrique, Alejandro ^a   Marqués, Elia ^a   Calvo, Jorge ^a   Sesma, Alvaro G ^a   Cambra, Felix ^a   Abradelo, Manuel ^a   Sterup, Rose Marie L ^a   Olivares, Sergio ^a   Justo, Iago ^a   Colina, Francisco ^b   Moreno, Enrique ^a  

^a Service of General Surgery Alimentary Tract and Abdominal Organ Transplantation   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

De novo tumors; Immunosuppression; Liver transplantation; Rapamycin; Sirolimus; Sirolimus monotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CHOLESTEROL; CREATININE; CYCLOSPORIN A; GLUCOSE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ACUTE LIVER FAILURE; ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BUDD CHIARI SYNDROME; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; TUMOR LOCALIZATION;

CALCINEURIN; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEOPLASMS; RISK FACTORS; SIROLIMUS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79955018514     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Jain AB, Yee LD, Nalesnik MA, et al: Comparative incidence of de novo non-lymphoid neoplasms after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193-1200. (Pubitemid 28530324)
2. Ojo AO, Held PJ, Port FK, et al: Chronic renal failure after transplantation of a non-renal organ. N Engl J Med 2003; 349: 931-940. (Pubitemid 37064766)
3. Guba M, Graeb C, Jauch KW, Geissler EK: Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777-1782. (Pubitemid 38822196)
4. Wiessner RH, Demetris AJ, Belle S, et al: Acute hepatic allograft rejection: Incidence, risk factors and impact on outcome. Hepatology 1998; 28: 638-645. (Pubitemid 28405409)
5. Seghal SN: Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340.
6. Guba M, Breitenbuch P, Steinbauer M, et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135. (Pubitemid 34155123)
7. Koehl GE, Andrassy J, Guba M, et al: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319-1326. (Pubitemid 38668421)
8. Guilbeau JM: Delayed wound healing with sirolimus after liver transplantation. Ann Pharmacother 2002; 36: 1391-1395.
9. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ: Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079-1085. (Pubitemid 37304464)
10. Fischer A, Seguel JM, de la Torre AN, et al: Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl 2004; 10: 193-198. (Pubitemid 38240117)
11. Montalbano M, Neff GW, Yamashiki N, et al: A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimusrelated complications. Transplantation 2004; 78: 264-268.
12. Kneteman NM, Oberholzer J, Al Saghier M, et al: Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-1311. (Pubitemid 39406087)
13. Dunkelberg JC, Trotter JF, Wachs M, et al: Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003; 9: 463-468. (Pubitemid 36621713)
14. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV: Conversion to sirolimus: A successful treatment for post transplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762.
15. Sierka D, Kumar MSA, Heifets M, Parikh M, Moritz MJ, Kumar A: Successful minimization of immunosuppression and conversion to sirolimus in kidney transplant recipients with post transplant lymphoproliferative disease and de novo nonskin malignancies. Am J Transplant 2004; 4(Suppl. 8): 523.
16. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD: Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889. (Pubitemid 41552882)
17. Campistol JM, Eris J, Oberbauer R, et al: Sirolimus therapy after cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589.
18. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J: Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005; 79: 855-857. (Pubitemid 40546211)
19. Nair S, Eason J, Loss G: Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126-129. (Pubitemid 36204562)
20. Maheshwari A, Torbenson MS, Thuluvath PJ: Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation. Dig Dis Sci 2006; 51: 1677-1684.
21. Di Benedetto F, di Sandro S, de Ruvo N, et al: Sirolimus monotherapy in liver transplantation. Transplant Proc 2007; 39: 1930-1932.
22. Diekmann F, Gutierrez-Dalmau A, Torregrosa JV, Oppenheimer F, Campistol JM: Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation. A pilot experience. Transplantation 2005; 80: 1344-1348.
23. th edition. New York: Springer-Verlag, 2002.
24. Jain A, Reyes J, Kashyap R, et al: Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232: 490-500.
25. Jonas S, Rayes N, Neumann U, et al: De novo malignancies after liver transplantation using tacrolimusbased protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997;80: 1141-1150. (Pubitemid 27427615)
26. Kelly D, Emre S, Guy SR, Miller CM, Schartz ME, Sheiner PA: Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998; 83: 1237-1243. (Pubitemid 28419079)
27. Haagsma EB, Hagens VE, Schaapveld M, et al: Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91. (Pubitemid 32102556)
28. Sánchez EQ, Marubashi S, Jung G, et al: De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002; 8: 285-291. (Pubitemid 34257212)
29. Jiménez C, Rodríguez D, Marqués E, et al: De novo tumors after liver transplantation. Transplant Proc 2002; 34: 297-298.
30. Benlloch S, Berenguer M, Prieto M, et al: De novo internal neoplasms after liver transplantation: Increased risk and aggressive behavior in recent years? Am J Transplant 2004; 4: 596-604.
31. Herrero JI, Lorenzo M, Quiroga J, et al: De novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival. Liver Transpl 2005; 11: 89-97. (Pubitemid 40124447)
32. Gonzalez-Chamorro A, Jiménez C, Moreno E, et al: Management and outcome of liver recipients with posttransplant lymphoproliferative disease. Hepatogastroenterology 2000; 47: 211-219. (Pubitemid 30085415)
33. Mithoefer AB, Supran S, Freeman RB: Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002; 8: 939-944. (Pubitemid 35154026)
34. Duvoux C, Delacroix I, Richardet JP, et al: Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 1999; 67: 418-421. (Pubitemid 29094014)
35. Jiménez C, Marqués E, Loinaz C, et al: Upper aerodigestive tract and lung tumors after liver transplantation. Transplant Proc 2003; 35: 1900-1901. (Pubitemid 37093756)
36. Jiménez C, Manrique A, Marqués E, et al: Incidence and risk factors for the development of lung tumors after liver transplantation. Transplant Int 2007; 20: 57-63.
37. Vera A, Gunson BK, Ussatoff V, et al: Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003; 75: 1983-1988. (Pubitemid 36793279)
38. Jain A, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J: Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70: 1335-1342.
39. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J: Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002; 8: 482-487. (Pubitemid 34520778)
40. Kengott S, Gerbes AL, Schauer R, Bilzer M: Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcoholic-induced cirrhosis. Transplant Int 2003; 16: 639-641. (Pubitemid 37193291)
41. Presser SJ, Schumacher G, Neuhaus R, Thuss-Patience P, Stieler J, Neuhaus P: De novo esophageal neoplasia after liver transplantation. Liver Transpl 2007; 13: 443-450. (Pubitemid 46444474)
42. Dumortier J, Guillaud O, Adham M, et al: Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol 2007; 102: 1032-1041. (Pubitemid 46698218)
43. Peyregne V, Ducerf C, Adham M, et al: De novo cancer after orthotopic liver transplantation. Transplant Proc 1998; 30: 1484-1485. (Pubitemid 28309655)
44. Toso C, Meeberg GA, Bigam DL, et al: De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162-1168.